Takeda Adds Exelixis Arrow To Oncology Quiver

Takeda's acquisition of Japanese rights to Exelixis' lead product fills a gap in the oncology portfolio while adding another piece to the US company's global licensing jigsaw.

Kidneys

Takeda Pharmaceutical Co. Ltd. has paid $50m upfront to acquire exclusive commercialization rights in Japan to Exelixis Inc.'s oral small molecule cancer drug cabozantinib, for all potential indications including advanced renal cell carcinoma (RCC).

South San Francisco-based Exelixis is also eligible for further development, regulatory and first sales milestone payments totaling up to $95m...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from Business

Quick Listen: Scrip’s Five Must-Know Things

 
• By 

In this week's episode: J&J delivers in Q2 despite Stelara drop; Sarepta cuts jobs as Elevidys slumps; AI is inevitable but needs to be applied appropriately; China’s mid-cap companies thrive; and a look behind Glenmark’s landmark trispecific deal.

Chief Strategist O’Hara On Novavax’s Partnership-Focused Approach

 
• By 

A deal last year with Sanofi relieved Novavax of commercial costs for the COVID-19 vaccine Nuvaxovid, allowing the company to focus on R&D and finding partners for its other vaccines.

After Gilead Deal, Hookipa Hangs Up Its Hat

 
• By 

The Austrian firm is delisting from the NASDAQ and closing down.

Genentech Gets Columvi Complete Response Following ODAC’s No

 
• By 

Seeking to move Columvi into second-line DLBCL, Genentech got an FDA letter saying the Phase III STARGLO study’s benefits may have been driven by results in Asian enrollees.

More from Scrip

Pharma Gets A Compatriot At CDER With Tidmarsh Appointment To Top Spot

 

Drug manufacturers may find comfort in the appointment of former biotech CEO and entrepreneur George Tidmarsh to lead the FDA’s Center for Drug Evaluation and Research.

Alkermes To Advance Alixorexton After Positive Phase II Narcolepsy Results

 

The biotech company is planning for Phase III based on positive topline results from Vibrance-1 in narcolepsy type 1 and remains optimistic about type 2 disease.

After Gilead Deal, Hookipa Hangs Up Its Hat

 
• By 

The Austrian firm is delisting from the NASDAQ and closing down.